Roivant Sciences Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ROIV research report →
About the company
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia.
- CEO
- Matthew Gline
- IPO
- 2020
- Employees
- 908
- HQ
- London, GB
Price Chart
- Market Cap
- $25.27B
- P/E
- -78.07
- P/S
- 3059.07
- P/B
- 5.45
- EV/EBITDA
- -91.69
- Div Yield
- 0.00%
- Gross Margin
- 84.44%
- Op Margin
- -15560.57%
- Net Margin
- -3629.19%
- ROE
- -6.85%
- ROIC
- -23.55%
- Revenue
- $8.26M · -71.57%
- Net Income
- $-299,771,000 · -74.30%
- EPS
- $-0.43 · -79.17%
- Op Income
- $-1,285,303,000
- FCF YoY
- 10.13%
- 52W High
- $35.90
- 52W Low
- $10.71
- 50D MA
- $30.02
- 200D MA
- $24.48
- Beta
- 1.11
- Avg Volume
- 5.88M
Get TickerSpark's AI analysis on ROIV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Gline Matthew | other | 76,171 |
| Jun 30, 26 | Fitzgerald Meghan | other | 10,000 |
| Jun 30, 26 | Fitzgerald Meghan | sell | 10,000 |
| Jun 30, 26 | Fitzgerald Meghan | other | 10,000 |
| Jun 30, 26 | Torti Frank | other | 40,310 |
| Jun 30, 26 | Sukhatme Mayukh | other | 46,878 |
| Jun 29, 26 | Epperly Melissa B, | other | 17,750 |
| Jun 29, 26 | Epperly Melissa B, | other | 17,750 |
| Jun 29, 26 | Epperly Melissa B, | sell | 15,002 |
| Jun 29, 26 | Epperly Melissa B, | sell | 2,748 |
Our ROIV coverage
Recent articles, reports, and earnings notes.
Roivant Sciences (ROIV): Cash-Rich Biotech Catalysts Ahead
Roivant pairs a $4.3B cash base with multiple late-stage catalysts, led by brepocitinib’s near-term launch path and several 2H 2026 readouts. The stock looks like a selective Buy, but execution risk remains high given heavy cash burn and limited current revenue.
Summit Therapeutics is acting like dilution no longer matters
Summit Therapeutics is trading like the financing scare already came and went. The rebound says the market cares more about ivonescimab's November 14, 2026 FDA clock and funded Phase III runway than a headline offering that never even closed.
Roivant Sciences Ltd. (ROIV) climbs above 52-week high
Roivant Sciences Ltd. (ROIV) climbs after hours following its May 20 earnings and business update. The biotech’s rally is tied to encouraging pipeline progress, strong cash reserves, and analyst optimism, pushing shares above their prior 52-week high as investors reassess the company’s platform value.
Want a deeper read on ROIV?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.